Heterogeneity of IFN-Mediated Responses and Tumor Immunogenicity in Patients with Cervical Cancer Receiving Concurrent Chemoradiotherapy

Abstract

Purpose: To ask whether the expression of immune markers and IFN signaling in tumor biopsies changes during concurrent chemoradiotherapy (CCRT). Experimental Design: Tumor biopsies and peripheral mononuclear blood cells (PMBC) before and immediately after 20 Gy/10 fractions (F) of radiation treatment (RT) from 30 patients with cervical cancer receiving CCRT were evaluated by IHC and qRT-PCR for immune markers and correlated with the short-term response. Results: Tumor immune response to radiation before and after 10F RT as reflected by CD8+ T-cell infiltration had substantial heterogeneity with increases, decreases, and no change all evident. Increases in CD8+ T cells during CCRT correlated with the presence of nuclear IRF1 in tumor cells (r = 0.68, P < 0.0001) and the patient short-term response (P < 0.01). Similarly, in a subset of patients (∼40%) PD-L1 positivity in tumor cells increased, which also correlated with nuclear IRF1 staining (r = 0.48, P < 0.01). Patients with augmented PMBC IFN signature expression after 10F had a significantly higher probability of PD-L1 induction (83% vs. 7%, P < 0.0001). Most patients exhibited abundant expression of SERPINB9 and CD47 in tumor cells, and tumor infiltration by CD68+ cells. SERPINB9 expression correlated with STAT1 signaling in tumor cells. Conclusions: CCRT leads to differential tumor immunogenicity and IFN signaling in patients with cervical cancer, suggesting radiation induction of immunity is limited to a subset of patients and may reflect the heterogeneity of intratumoral induction of IFNs. See related commentary by Mondini and Deutsch, p. 3815

Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion

“…Immune checkpoint expression often changes following therapy 8 , 26 – 28 . To determine whether chemotherapy alters the expression of CD47, we performed immunohistochemistry (IHC) analysis to assess CD47 protein levels in paired specimens from 81 osteosarcoma patients before and after chemotherapy.…”

Single-cell RNA-sequencing reveals radiochemotherapy-induced innate immune activation and MHC-II upregulation in cervical cancer

“…It is well-documented that RCT suppresses tumor growth and modulates anti-tumor immunity in various cancers. 6 , 7 In patients with CC, studies of bulk RNA-sequencing of immune cells have shown that RCT stimulates the expression of the co-stimulatory molecule CD28 8 and downregulates the expression of inhibitory molecules PD-1/PD-L1. 9 At the same time, multispectral flow cytometry of cervical smears revealed an early decrease in the number of T cells in the RCT-treated cervical TME, followed by an increase in their number at a later stage.…”

Radioimmunotherapy‐induced intratumoral changes in cervical squamous cell carcinoma at single‐cell resolution

“…As such, investigations into radioimmunotherapy‐induced tumor ecosystem evolution are essential for guiding improvements in treatment strategies that achieve better long‐term disease control. To date, several studies have investigated radiochemotherapy‐induced tumor ecosystem evolution using bulk RNA‐sequencing and immune staining [ 7 , 8 ]. However, these findings were limited owing to the cellular heterogeneity in cancers.…”